---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-006912"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:56:08.670692+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports 2025 net operating income $1.6M; net loss narrows to $1.0M

## Summary
- Product sales $27.6M, up 4.3% YoY; gross margin improved to 41.4% from 30%.
- Net loss $1.0M ($0.12/share) vs $2.2M ($0.26/share) in 2024.
- Net operating income $1.6M vs operating loss $1.6M in 2024.
- Non-recurring items: $2.7M Re-Tain write-down, $651K colostrum write-downs, $297K CEO transition costs, $427K insurance proceeds.
- Cash $3.8M, no debt draw; net working capital $13M.

## SEC filing metadata
- accession: 0001437749-26-006912
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000143774926006912/0001437749-26-006912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000143774926006912/iccc20260304_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-006912
- JSON: https://secwatch.observer/filing/0001437749-26-006912.json
- Plain text: https://secwatch.observer/filing/0001437749-26-006912.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.